Novo Nordisk Investors
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.
Funding Status:
IPO
Industry:
End-to-End Drug Development
Estimated Revenue:
$1B to $10B
Technology:
Biotechnology, Health Care, Science and Engineering
Acquisitions Number:
8
Number Of Exists:
4
Headquarters:
Bagsværd
Total Funding:
22000000
Last Funding Date:
2018-12-05 00:00:00
Last Funding Type:
Post-IPO Equity
Investor Type:
Undisclosed
Employee Number:
64319
Investors Number:
14
Investment Stage:
N/A
Founded Date:
1923-12-21